A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities

What Was Tested

In this phase 2 trial, researchers set out to test Ecnoglutide.

It had six arms (groups): Schedule A: VRB-101 (Active Arm 1) (experimental), Schedule A: VRB-101 (Active Arm 2) (experimental), Schedule A: VRB-101 (Active Arm 3) (experimental), Schedule B: VRB-101 (Active Arm 4) (experimental) and Schedule B: VRB-101 (Active Arm 5) (experimental).

Participants will receive VRB-101 once every week.

Participants will receive VRB-101 once every week.

Participants will receive VRB-101 once every week.

The registry classes the interventions as drug.

More on the Plan

This is a randomized, double-blind, placebo-controlled study of oral ecnoglutide (VRB-101), with 5 active arms and 1 placebo arm.

The study will include a Screening Period of 4 weeks, followed by a 20-week Study Treatment Period and a 4-week Safety Follow-up Period prior to the end of study (EOS) visit.

Who Took Part

206 actual participants took part.

It was open to people of any sex aged from 18 years up to 80 years.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Have a BMI of ≥30 kg/m2 OR ≥27 kg/m2 and \<30 kg/m2 with at least 1 weight-related comorbidity. Participants of childbearing potential must be non-pregnant and non-lactating and must agree to use study-specified contraceptive methods.

The full record lists 4 inclusion and 4 exclusion criteria.

How the Study Was Run

It was run as a randomized, parallel-group and triple-blind study.

The participants were allocated by chance, so the Ecnoglutide group and the comparison group should start out alike.

Groups ran in parallel: each of the participants stayed in one arm throughout.

Blinding on both sides kept the participants and researchers unaware of who received Ecnoglutide.

Those kept unaware of assignments: participant, care provider and investigator.

It started in 2025-11-25 with completion listed for 2026-07-23.

It ran at 22 sites in United States (22).

Its stated primary purpose is treatment.

What Was Measured

The main thing measured (primary outcome): Mean percent change from baseline in body weight (time frame: From Baseline (Day 0) up to Week 21).

It also tracked 6 secondary outcomes, for example Absolute change from baseline in body weight, Change from baseline in body mass index (BMI), Number of study participants with treatment emergent adverse events (TEAEs) and serious adverse events (SAEs), Change from baseline in blood pressure (BP) and Change from baseline in Columbia-Suicide Severity Rating Scale (C-SSRS).

What This Means in Plain Language

Put simply, this is a phase 2, randomized trial of Ecnoglutide in 206 people.

The trial is marked completed; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Ecnoglutide compound page, all human trials.